Climb Bio (CLYM) Net Income towards Common Stockholders (2020 - 2026)
Climb Bio (CLYM) reported Net Income towards Common Stockholders of -$13.7 million for Q1 2026, up 33.93% on a YoY basis from -$10.2 million in Q1 2025, and up 21.6% quarter-over-quarter from -$17.5 million in Q4 2025.
Climb Bio (CLYM) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Climb Bio has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$13.7 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 33.93% year-over-year to -$13.7 million; the trailing twelve-month figure through Mar 2026 stood at -$52.5 million (up 43.49% YoY), and the FY2025 full-year result was -$59.6 million, up 19.39% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$13.7 million, up from -$17.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$1.7 million in Q1 2024, with the low at -$54.9 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged -$13.4 million across 5 years, with a median of -$9.7 million in 2022.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 92.62% — and 2025, when it sank 1145.85%.
- Climb Bio's Net Income towards Common Stockholders stood at -$7.8 million in 2022, then jumped by 51.39% to -$3.8 million in 2023, then plunged by 122.37% to -$8.4 million in 2024, then slumped by 108.22% to -$17.5 million in 2025, then advanced by 21.6% to -$13.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$13.7 million (Q1 2026), -$17.5 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | -13.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.70 Mn |
| Dec 31, 2025 | -17.47 Mn |
| Sep 30, 2025 | -12.86 Mn |
| Jun 30, 2025 | -8.50 Mn |
| Mar 31, 2025 | -20.73 Mn |
| Dec 31, 2024 | -8.39 Mn |
| Sep 30, 2024 | -8.95 Mn |
| Jun 30, 2024 | -54.89 Mn |
| Mar 31, 2024 | -1.66 Mn |
| Dec 31, 2023 | -3.77 Mn |
| Sep 30, 2023 | -3.74 Mn |
| Jun 30, 2023 | -5.60 Mn |
| Mar 31, 2023 | -22.54 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -9.68 Mn |
| Jun 30, 2022 | -14.60 Mn |
| Mar 31, 2022 | -13.20 Mn |
| Dec 31, 2021 | -10.55 Mn |
| Sep 30, 2021 | -10.94 Mn |
| Jun 30, 2021 | -10.86 Mn |